Nathalie Van Den Berghe
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease.
Journal: Therapeutic advances in gastroenterology
Published: October 20, 2022
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: September 21, 2021
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations.
Journal: Journal of Crohn's & colitis
Published: November 27, 2020
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.
Journal: Journal of pharmaceutical and biomedical analysis
Published: March 23, 2020
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.
Journal: Journal of pharmaceutical and biomedical analysis
Published: November 04, 2019
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Journal: Clinical pharmacology and therapeutics
Published: May 08, 2019
Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 06, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Journal: Journal of Crohn's & colitis
Published: November 27, 2018
Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy.
Journal: The Journal of investigative dermatology
Published: November 23, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
Journal: Journal of gastroenterology and hepatology
Published: October 04, 2018
Last Updated: 09/26/2026